Sun Pharma Tumbles 6% as Trump Tariff Threat Shakes Sector

Market Reacts to Potential US Drug Tariffs

The Indian stock market saw significant pressure on the pharmaceutical sector, with the Nifty Pharma index experiencing a sharp correction. Leading the decline were major industry players Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories, which were among the worst-performing Nifty stocks for the week, both falling over 6%. The sell-off was triggered by a news report indicating that the Trump administration in the United States is considering imposing steep tariffs on drugmakers that have not secured pricing agreements within the US.

Details of the Proposed Tariff

According to a Bloomberg report, the US administration is set to announce tariffs, potentially as high as 100%, on imported branded and patented medicines. This measure is aimed at companies that do not have existing deals guaranteeing lower drug prices for American consumers and are not currently in negotiations. The move is part of a broader effort to compel global drugmakers to either lower their prices or increase their manufacturing presence in the United States. However, the report also noted that the plans are not yet finalized and could be subject to change, with possible exemptions for certain medicines and disease categories.

Why Sun Pharma is in Focus

Sun Pharma became the focal point of investor concern due to its significant exposure to the US market, particularly in the branded and specialty drug segments. It is among the Indian pharmaceutical companies with the largest presence in the US. For the fiscal year 2025, Sun Pharma's US sales grew by 5.8% to reach ₹16,200 crore, which accounted for a substantial 31% of the company's total consolidated sales. This reliance on the US market has been growing, up from 18% of total sales in FY24.

The company's specialty drug portfolio, which includes products like ILUMYA, CEQUA, WINLEVI, and ODOMZO, contributes around 19% to its total revenue. This segment is perceived to be directly at risk if the proposed tariffs are implemented. The uncertainty led to Sun Pharma's stock tumbling as much as 6% during intraday trading, hitting a low of ₹1,635 on the BSE.

Broader Impact on the Pharma Sector

The tariff fears were not confined to Sun Pharma. A wave of selling hit other major pharmaceutical stocks as investors grew cautious about potential ripple effects. The market witnessed sharp declines across the board for companies with US exposure.

Another factor contributing to the pressure on the sector was the sharp appreciation of the Indian rupee, which can negatively impact the earnings of export-oriented companies like drug manufacturers.

Branded Drugs vs. Generics

Market analysts have pointed out a crucial distinction in the tariff's potential impact. The proposed measures are specifically targeted at branded and patented drugs, which are typically higher-priced. This means that multinational giants with deep pockets are the primary focus. In contrast, the tariffs are not aimed at generic drug manufacturers. Generics constitute approximately 90% of all prescriptions in the US and are the backbone of India's pharmaceutical exports. This distinction suggests that the direct financial impact on the broader Indian pharma industry, which is heavily reliant on generic exports, might be limited. The current market reaction is therefore seen by some as being driven more by sentiment than by a fundamental threat to the entire sector.

Potential Mitigation for Sun Pharma

For Sun Pharma, the path forward may involve strategic negotiations and investments. To avoid the tariffs, the company might need to incrementally strike a pricing deal with the US administration, increase its manufacturing investments within the US, or participate in the Trump RX platform. Sun Pharma already has manufacturing operations in the US, but it does not disclose the percentage of its sales derived from these facilities. Analysts also note that if some of Sun Pharma's products are shipped from Europe, they might fall under an existing trade deal that imposes a much lower 15% tariff, potentially softening the blow.

Stock Valuation and Analyst Outlook

Despite the immediate sell-off, the long-term outlook for Sun Pharma among analysts remains largely positive. According to Bloomberg data, out of 44 analysts tracking the company, 35 maintain a 'buy' rating. The stock is currently trading at approximately 33 times its projected FY27 price-to-earnings (PE) ratio. The average 12-month consensus price target suggests a potential upside of 22.1% from current levels, indicating that many analysts believe the company can navigate the current challenges.

Conclusion

The threat of 100% US tariffs has created significant short-term volatility for the Indian pharmaceutical sector, with Sun Pharma bearing the brunt of the impact due to its branded drug portfolio. While the broader, generic-focused industry appears relatively insulated, the situation highlights the risks associated with heavy reliance on the US market. The final impact will depend on whether the proposed tariffs are implemented and in what form. For now, investors will be closely watching for any official announcements from the US and strategic responses from companies like Sun Pharma.